Helen Heslop, MD

Adjunct Professor of Medicine, Academic Institute
Full Affiliate Member, Research Institute
Houston Methodist


Dr. Heslop's initial faculty appointment was as Assistant Member of the Division of Bone Marrow Transplantation in the Department of Hematology-Oncology at the St. Jude Children's Research Hospital, in Memphis in 1991. She was promoted to Associate Member in 1994. She also held an appointment as Associate Professor in the Department of Pediatrics at the University of Tennessee in Memphis. Dr. Heslop received her current appointments at the Baylor College of Medicine in Houston, Texas in 1997. She was named as the first Dan L. Duncan Chair for Baylor College of Medicine in 2006.

Description of Research

Dr. Heslop's research centers on adoptive immunotherapy with gene-modified effector cells to improve hemopoietic stem cell transplantation and cancer therapy. She currently directs a Lymphoma SPORE program and a program project grant from the NCI, as well as a Specialized Center of Research from the Leukemia and Lymphoma Society. Her research focus is to develop safe and effective T-cell immunotherapies for lymphoma and other Epstein-Barr virus-associated malignancies, including Hodgkin's Disease and nasopharyngeal cancer. Dr. Heslop also runs studies using third party CTLs to treat viral infections after transplant.

Areas Of Expertise

Cancer Adoptive immunotherapy Effector cells Hemopoietic stem cell transplantation

Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas
Heslop, HE, Sharma, S & Rooney, CM 2021, , Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 39, no. 5, pp. 514-524. https://doi.org/10.1200/JCO.20.01709

Taking T-Cell Oncotherapy Off-the-Shelf
Mo, F, Mamonkin, M, Brenner, MK & Heslop, HE 2021, , Trends in Immunology, vol. 42, no. 3, pp. 261-272. https://doi.org/10.1016/j.it.2021.01.004

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
Ramos, CA, Grover, NS, Beaven, AW, Lulla, PD, Wu, MF, Ivanova, A, Wang, T, Shea, TC, Rooney, CM, Dittus, C, Park, SI, Gee, AP, Eldridge, PW, McKay, KL, Mehta, B, Cheng, CJ, Buchanan, FB, Grilley, BJ, Morrison, K, Brenner, MK, Serody, JS, Dotti, G, Heslop, HE & Savoldo, B 2020, , Journal of Clinical Oncology, vol. 38, no. 32, pp. 3794-3804. https://doi.org/10.1200/JCO.20.01342

Modulating tnfa activity allows transgenic il15-expressing cll-1 car t cells to safely eliminate acute myeloid leukemia
Ataca Atilla, P, McKenna, MK, Tashiro, H, Srinivasan, M, Mo, F, Watanabe, N, Simons, BW, McLean Stevens, A, Redell, MS, Heslop, HE, Mamonkin, M, Brenner, MK & Atilla, E 2020, , Journal for immunotherapy of cancer, vol. 8, no. 2, e001229. https://doi.org/10.1136/jitc-2020-001229

The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma
Lulla, PD, Tzannou, I, Vasileiou, S, Carrum, G, Ramos, CA, Kamble, R, Wang, T, Wu, M, Bilgi, M, Gee, AP, Mukhi, S, Chung, B, Wang, L, Watanabe, A, Kuvalekar, M, Jeong, M, Li, Y, Ketkar, S, French-Kim, M, Grilley, B, Brenner, MK, Heslop, HE, Vera, JF & Leen, AM 2020, , Science translational medicine, vol. 12, no. 554, eaaz3339. https://doi.org/10.1126/SCITRANSLMED.AAZ3339

Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma
Hegde, M, Joseph, SK, Pashankar, F, DeRenzo, C, Sanber, K, Navai, S, Byrd, TT, Hicks, J, Xu, ML, Gerken, C, Kalra, M, Robertson, C, Zhang, H, Shree, A, Mehta, B, Dakhova, O, Salsman, VS, Grilley, B, Gee, A, Dotti, G, Heslop, H, Brenner, MK, Wels, WS, Gottschalk, S & Ahmed, N 2020, , Nature Communications, vol. 11, no. 1, 3549. https://doi.org/10.1038/s41467-020-17175-8

Virus-Specific T Cells for the Treatment of Malignancies—Then, Now, and the Future
Sharma, S, Leung, WK & Heslop, HE 2020, , Current Stem Cell Reports, vol. 6, no. 2, pp. 17-29. https://doi.org/10.1007/s40778-020-00170-6

Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network
Levine, JE, Antin, JH, Allen, CE, Burroughs, LM, Cooke, KR, Devine, S, Heslop, H, Nakamura, R, Talano, JA, Yanik, G & DiFronzo, N 2020, , Biology of Blood and Marrow Transplantation, vol. 26, no. 5, pp. e94-e100. https://doi.org/10.1016/j.bbmt.2020.01.024

Sensitizing Burkitt lymphoma to EBV-CTLs
Heslop, HE 2020, , Blood, vol. 135, no. 21, pp. 1822-1823. https://doi.org/10.1182/BLOOD.2020005492

CRISPR-Edited Immune Effectors: The End of the Beginning
Mo, F, Heslop, H & Mamonkin, M 2020, , Molecular Therapy, vol. 28, no. 4, pp. 995-996. https://doi.org/10.1016/j.ymthe.2020.03.009

Incorporation of thiotepa in a reduced intensity conditioning regimen may improve engraftment after transplant for HLH
Naik, S, Eckstein, O, Sasa, G, Heslop, H, Krance, RA, Allen, C & Martinez, C 2020, , British Journal of Haematology, vol. 188, no. 6, pp. e84-e87. https://doi.org/10.1111/bjh.16370

Engineered off-the-shelf therapeutic T cells resist host immune rejection
Mo, F, Watanabe, N, McKenna, MK, Hicks, MJ, Srinivasan, M, Gomes-Silva, D, Atilla, E, Smith, T, Ataca Atilla, P, Ma, R, Quach, D, Heslop, HE, Brenner, MK & Mamonkin, M 2021, , Nature Biotechnology, vol. 39, no. 1, pp. 56-63. https://doi.org/10.1038/s41587-020-0601-5

T-cell receptor stimulation enhances the expansion and function of CD19 chimeric antigen receptor–expressing T cells
Lapteva, N, Gilbert, M, Diaconu, I, Rollins, LA, Al-Sabbagh, M, Naik, S, Krance, RA, Tripic, T, Hiregange, M, Raghavan, D, Dakhova, O, Rouce, RH, Liu, H, Omer, B, Savoldo, B, Dotti, G, Cruz, CR, Sharpe, K, Gates, M, Orozco, A, Durett, A, Pacheco, E, Gee, AP, Ramos, CA, Heslop, H, Brenner, M & Rooney, CM 2019, , Clinical Cancer Research, vol. 25, no. 24, pp. 7340-7350. https://doi.org/10.1158/1078-0432.CCR-18-3199

Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)
Kansagra, AJ, Frey, NV, Bar, M, Laetsch, TW, Carpenter, PA, Savani, BN, Heslop, HE, Bollard, CM, Komanduri, KV, Gastineau, DA, Chabannon, C, Perales, MA, Hudecek, M, Aljurf, M, Andritsos, L, Barrett, JA, Bachanova, V, Bonini, C, Ghobadi, A, Gill, SI, Hill, JA, Kenderian, S, Kebriaei, P, Nagler, A, Maloney, D, Liu, HD, Shah, NN, Kharfan-Dabaja, MA, Shpall, EJ, Mufti, GJ, Johnston, L, Jacoby, E, Bazarbachi, A, DiPersio, JF, Pavletic, SZ, Porter, DL, Grupp, SA, Sadelain, M, Litzow, MR, Mohty, M & Hashmi, SK 2019, , Bone Marrow Transplantation, vol. 54, no. 11, pp. 1868-1880. https://doi.org/10.1038/s41409-019-0451-2

T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy
Keller, MD, Darko, S, Lang, H, Ransier, A, Lazarski, CA, Wang, Y, Hanley, PJ, Davila, BJ, Heimall, JR, Ambinder, RF, Barrett, AJ, Rooney, CM, Heslop, HE, Douek, DC & Bollard, CM 2019, , British Journal of Haematology, vol. 187, no. 2, pp. 206-218. https://doi.org/10.1111/bjh.16053

Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study
Naik, S, Riches, M, Hari, P, Kim, S, Chen, M, Bachier, C, Shaughnessy, P, Hill, J, Ljungman, P, Battiwalla, M, Chhabra, S, Daly, A, Storek, J, Ustun, C, Diaz, MA, Cerny, J, Beitinjaneh, A, Yared, J, Brown, V, Page, K, Dahi, PB, Ganguly, S, Seo, S, Chao, N, Freytes, CO, Saad, A, Savani, BN, Woo Ahn, K, Boeckh, M, Heslop, HE, Lazarus, HM, Auletta, JJ & Kamble, RT 2019, , Transplant Infectious Disease, vol. 21, no. 5, e13145. https://doi.org/10.1111/tid.13145

Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients
Naik, S, Martinez, CA, Omer, B, Sasa, G, Yassine, K, Allen, CE, Kamdar, K, Orth, R, Wu, M, Leung, K, Gottschalk, S, Brenner, MK, Heslop, H & Krance, RA 2019, , Blood Advances, vol. 3, no. 18, pp. 2689-2695. https://doi.org/10.1182/bloodadvances.2018026203

"mini" bank of only 8 donors supplies CMV-directed T cells to diverse recipients
Tzannou, I, Watanabe, A, Naik, S, Daum, R, Kuvalekar, M, Leung, KS, Martinez, C, Sasa, G, Wu, M, Gee, AP, Krance, RA, Gottschalk, S, Heslop, H & Omer, B 2019, , Blood Advances, vol. 3, no. 17, pp. 2571-2580. https://doi.org/10.1182/bloodadvances.2019000371

Epigenetic Inhibition Puts Target Antigen in the Crosshairs of CAR T Cells
Steffin, DHM & Heslop, HE 2019, , Molecular Therapy, vol. 27, no. 5, pp. 900-901. https://doi.org/10.1016/j.ymthe.2019.04.007

Harmonizing Immune Effector Toxicity Reporting
Heslop, HE & Shpall, EJ 2019, , Biology of Blood and Marrow Transplantation, vol. 25, no. 4, pp. e121-e122. https://doi.org/10.1016/j.bbmt.2019.01.001